Twist Bioscience Corporation stocks have been trading up by 11.95 percent amid upbeat sentiment surrounding its latest synthetic biology advances.
Click Here for a Millionaire's POV on Trading TWST
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways
- Evercore ISI raised its price target on Twist Bioscience to $56 from $52 and reiterated an Outperform rating in its Q1 medical technology and life science tools preview.
- Guggenheim raised its price target on Twist Bioscience from $50 to $55 and reiterated a Buy rating after updating its models and forecasts following management meetings.
- An insider or large shareholder of Twist Bioscience has filed multiple Form 144s, signaling an intent to sell restricted or control securities of the company under SEC Rule 144.
Live Update At 12:32:13 EDT: On Tuesday, April 14, 2026 Twist Bioscience Corporation stock [NASDAQ: TWST] is trending up by 11.95%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
TWST has been grinding higher over the past few weeks, and the tape shows it. From 2026/03/20 around the low-$40s, Twist Bioscience stock has pushed into the mid‑$50s, closing near $56.40 on 2026/04/14 after trading as high as $59 intraday. That is a strong trend move of roughly 30% in less than a month, the kind of momentum swing active traders hunt for.
On the intraday chart, TWST opened around $50.96 and quickly surged above $52, then stair‑stepped its way into the high‑$50s before cooling off near the close. The steady series of higher lows through the morning shows aggressive dip buying, not just a one‑and‑done spike.
More Breaking News
- CRCL Stock Sees Profit Taking As Stablecoin Tailwinds Build
- Sky Quarry Inc. Faces Challenges Amidst Financial Struggles
- EOSE Stock Climbs As Preliminary Q1 Revenue And Capacity Ramp Impress Traders
- SYRE Stock Jumps As Stifel Hikes Target Ahead Of Key Data
Fundamentally, Twist Bioscience is still a high‑growth, money‑losing name. Quarterly revenue sits around $103.7M, with gross margin of 51.6%, but EBIT margin is deep in the red at -32.2% and profit margins are negative. The latest quarter shows a net loss of about $30.5M and free cash flow around -$34.8M. However, TWST holds about $148.6M in cash and has a current ratio of 3.8, giving the company runway to keep building. For traders, that combo — strong revenue growth, solid gross margin, and ongoing losses — screams “story stock” where sentiment and catalysts drive the chart.
Why Traders Are Watching TWST Right Now
Two bullish analyst calls have thrown fresh fuel on the TWST move. Evercore ISI lifted its Twist Bioscience price target to $56 from $52 and kept an Outperform rating in its Q1 med‑tech and life science tools preview. That new target essentially lines up with where TWST just traded, telling traders that the stock has run right into Wall Street’s updated goalpost. When a respected firm raises targets into strength, it often validates a breakout and keeps momentum traders engaged.
Guggenheim added more juice days earlier, bumping its Twist Bioscience target from $50 to $55 and reiterating a Buy rating after management meetings and updated models. That detail matters. It tells traders Guggenheim dug through the numbers with the team at Twist Bioscience and came away more confident, not less. In a name with negative earnings and heavy spending, that kind of direct channel check helps explain why TWST has been able to hold gains rather than fade.
At the same time, the Form 144 filings hanging over Twist Bioscience act as a reality check. Multiple filings signal that an insider or large holder plans to sell restricted or control shares under Rule 144. Form 144s do not mean panic by default, but they can create an overhang. Bigger supply waiting in the wings sometimes caps rallies or adds volatility when the tape gets heavy.
For short‑term traders, that mix — rising targets from Evercore ISI and Guggenheim, a strong trend, but looming potential insider sales — sets up a classic battleground. Breakouts in TWST above the recent $59 area could attract continuation traders, while any sharp pullback tied to selling pressure may draw in dip buyers who still trust the analyst narrative.
Conclusion
TWST is acting like a textbook momentum name right now. Twist Bioscience has climbed from the low‑$40s into the mid‑$50s on strong volume and steady bids, backed by fresh price target hikes from Evercore ISI and Guggenheim. Both firms reaffirmed positive ratings on Twist Bioscience, signaling they see upside as the company scales its synthetic biology and tools business, even though profits are still a long way off.
Under the hood, Twist Bioscience remains a high‑risk story. Margins are negative, the latest quarter shows a roughly $30M loss, and free cash flow trends are still sharply below zero. The balance sheet, with nearly $198M in cash and short‑term investments and modest debt, gives TWST time, but not forever. That is why the Form 144 filings matter. Planned sales by insiders or large holders in Twist Bioscience may add short‑term supply and shake out weak hands on any sharp dip.
For active traders, the message is simple: respect the trend, but respect risk even more. TWST is a strong mover with real catalysts, not a sleepy value play. As Tim Sykes loves to hammer home, “Cut losses quickly, because big winners are meaningless if you let one trade blow up your account.” As Tim Bohen, lead trainer with StocksToTrade says, “For me, trading is more about managing risk than finding the next big mover.” That mindset fits Twist Bioscience perfectly — ride the volatility if you choose, but always trade with a plan and treat TWST as an educational case study, not a guarantee.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.